Olaparib

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Olaparib
   1. Pharmacist Assessment Report
   2. Olaparib: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Olaparib: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Olaparib, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use identified is female breast carcinoma, which falls in the same disease category as an approved indication.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
female breast carcinoma	breast cancer

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
11503K	Lynparza	Tablet 100 mg	Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (PARP inhibitor), not a conventional cytotoxic
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the PI; haematological parameters (FBC) and renal function are usually monitored with PARP inhibitors
Handling Protection	Please refer to the PI and local cytotoxic or hazardous drug handling policies

Safety Considerations

Drug Interactions: The interaction screen returned 100 interacting drugs. Examples include:

• Major: aprepitant, dexamethasone, clarithromycin
• Moderate: metformin, bupropion, cimetidine, miconazole, clotrimazole, glyburide, ondansetron, repaglinide, rosuvastatin, simvastatin, alosetron, cisapride, and others
• Minor: prucalopride

Medicines such as aprepitant, dexamethasone and clarithromycin are common in oncology supportive care, so medication review is important.

For warnings and contraindications, please refer to the TGA-approved Product Information (PI).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---